Gamida Cell, a Jerusalem, Israel-based developer of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine, has closed a $10m Series E financing.
All major shareholders including Elbit Imaging, Clal Biotechnology Industries, Israel Healthcare Venture, Teva Pharmaceutical Industries, Amgen, Denali Ventures and Auriga Ventures participated in the round.
The company intends to use the capital for the global commercialization of its lead cell therapy product, StemEx, in development as an alternative therapeutic treatment for patients with blood cancers, such as leukemia and lymphoma, who can be cured by bone marrow transplantation but do not have a matched bone marrow donor
Gamida Cell is currently seeking a strategic partner to join in the global commercialization of StemEx.
The financing will also support the continued development of the company’s pipeline of products, primarily the NiCord® clinical trial for sickle cell disease and thalassemia.
Led by Mr. Reuven Krupik, chairman of the board and Dr. Yael Margolin, president and chief executive officer, Gamida plans to launch StemEx, which is being developed by the Gamida Cell-TEVA joint venture, in 2013.